Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
25
AEMD Quote, Financials, Valuation and Earnings
Last price:
$2.49
Seasonality move
:
16.15%
Day range:
$2.47 - $2.66
52-week range:
$2.66 - $84.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.33x
Volume:
48.6K
Avg. volume:
188.8K
1-year change:
-94.53%
Market cap:
$1.9M
Revenue:
--
EPS (TTM):
-$53.44
Analysts' Opinion
-
Consensus RatingAethlon Medical, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.38, Aethlon Medical, Inc. has an estimated upside of 365.23% from its current price of $2.49.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.75 representing 100% downside risk from its current price of $2.49.
Fair Value
-
According to the consensus of 2 analysts, Aethlon Medical, Inc. has 365.23% upside to fair value with a price target of $12.38 per share.
AEMD vs. S&P 500
-
Over the past 5 trading days, Aethlon Medical, Inc. has underperformed the S&P 500 by -10.8% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Aethlon Medical, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aethlon Medical, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Aethlon Medical, Inc. reported revenues of --.
Earnings Growth
-
Aethlon Medical, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Aethlon Medical, Inc. reported earnings per share of -$3.74.
Enterprise value:
-3.3M
EV / Invested capital:
-0.52x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.47x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$475.5K
Return On Assets:
-159.2%
Net Income Margin (TTM):
--
Return On Equity:
-228.41%
Return On Invested Capital:
-199.43%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $574.2K | -- | -- | -- | -- | |
| Gross Profit | $219.4K | -$488.9K | -$475.5K | -$226.1K | -$152.9K | |
| Operating Income | -$11.9M | -$11.6M | -$7.1M | -$2.9M | -$1.5M | |
| EBITDA | -$11.6M | -$11.1M | -$6.6M | -$2.7M | -$1.4M | |
| Diluted EPS | -$4.89 | -$2.85 | -$53.44 | -$0.20 | -$3.74 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $23.6M | $20.5M | $10.5M | $7.1M | $6.3M | |
| Total Assets | $23.9M | $23M | $12.8M | $8.8M | $7.3M | |
| Current Liabilities | $974.3K | $2.1M | $1.7M | $2.3M | $1.4M | |
| Total Liabilities | $974.3K | $3.2M | $2.5M | $2.8M | $1.6M | |
| Total Equity | $22.9M | $19.9M | $10.3M | $6M | $5.7M | |
| Total Debt | -- | $1.1M | $798.5K | $496.8K | $172.1K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$10.1M | -$8.9M | -$7.1M | -$2.2M | -$1.7M | |
| Cash From Investing | -$399.9K | -$13.7K | -- | -- | -- | |
| Cash From Financing | $1.1M | $5.6M | $6.1M | -$3.8K | $3.7M | |
| Free Cash Flow | -$10.5M | -$8.9M | -$7.1M | -$2.2M | -$1.7M | |
AEMD
Sector
Market Cap
$1.9M
$28M
Price % of 52-Week High
2.95%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-124.72%
-1.54%
1-Year Price Total Return
-93.99%
-17.48%
Beta (5-Year)
1.636
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.91
200-day SMA
Sell
Level
$15.85
Bollinger Bands (100)
Sell
Level
3.24 - 11.44
Chaikin Money Flow
Buy
Level
2M
20-day SMA
Sell
Level
$3.56
Relative Strength Index (RSI14)
Sell
Level
31.63
ADX Line
Sell
Level
19.24
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$4.35
MACD (12, 26)
Sell
Level
-0.52
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
21.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-33.9328)
Sell
CA Score
(Annual)
Level (-4.9547)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (15.4121)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment is involved in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce on April 17, 1991 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, AEMD has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The AEMD average analyst price target in the past 3 months is $12.38.
-
Where Will Aethlon Medical, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aethlon Medical, Inc. share price will rise to $12.38 per share over the next 12 months.
-
What Do Analysts Say About Aethlon Medical, Inc.?
Analysts are divided on their view about Aethlon Medical, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aethlon Medical, Inc. is a Sell and believe this share price will drop from its current level to $9.75.
-
What Is Aethlon Medical, Inc.'s Price Target?
The price target for Aethlon Medical, Inc. over the next 1-year time period is forecast to be $12.38 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is AEMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aethlon Medical, Inc. is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of AEMD?
You can purchase shares of Aethlon Medical, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aethlon Medical, Inc. shares.
-
What Is The Aethlon Medical, Inc. Share Price Today?
Aethlon Medical, Inc. was last trading at $2.49 per share. This represents the most recent stock quote for Aethlon Medical, Inc.. Yesterday, Aethlon Medical, Inc. closed at $2.49 per share.
-
How To Buy Aethlon Medical, Inc. Stock Online?
In order to purchase Aethlon Medical, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AEMD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AEMD
Sector
P/E ratio
--
23.89x
PEG ratio
0.00x
-0.01x
P/B ratio
0.33x
1.82x
Price / LTM sales
--
1.60x
Growth Metrics
AEMD
Sector
Revenue growth
--
4.62%
Earnings growth
-1757.5%
10.88%
Revenue (5-year growth)
-100%
6.5%
Earnings forecast
-$1.70
-$0.21
Profitability
AEMD
Sector
Profitability FY 2024
-$339.6K
$3.5M
Return on invested capital
-199.43%
-31.77%
Return on assets
-159.2%
-27.96%
Return on equity
-228.41%
-37.63%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Feb
11
Estimated Next Earnings Date
Feb
11
Balance Sheet
AEMD
Sector
Total cash
$5.9M
$26.3M
Short term investments
--
$25.7M
Total assets
$7.4M
$78M
Long term debt
$172.1K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
